One month after STZ administration, hallmarks of AD, including β-amyloid accumulation, phosphorylated tau protein, and neuroinflammation were observed in both the hippocampus and cortical regions (Moreira-Silva et al., 2019). Here, MAPT is linked to Alzheimer disease.